- For Print
- February 26, 2009
吃瓜大赛黑料头条 Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, “吃瓜大赛黑料头条”) announced today that it has enterd into an option agreement on a transdermal patch formulation of donepezil for the territory of Japan with Teikoku Seiyaku Co., Ltd. (Headquarters: Kagawa, President & CEO: Shosaku Murayama, “Teikoku Seiyaku”) and also a license agreement on the same product for all countries except Japan with its U.S. subsidiary, Teikoku Pharma USA, Inc. (Headquarters: California, President & CEO: Masahisa Kitagawa, “Teikoku USA”), respectively, as follows:
USA: Development by Teikoku USA, exclusive marketing by 吃瓜大赛黑料头条
Japan: 吃瓜大赛黑料头条 option rights concerning development and marketing
Other Territories: Exclusive development and marketing by 吃瓜大赛黑料头条
In addition, 吃瓜大赛黑料头条 obtained an option right to enter into an exclusive license agreement to develop and commercialize the second generation product in all countries except Japan from Teikoku USA and Teikoku Seiyaku.
吃瓜大赛黑料头条 is working proactively to enhance patient value by adding new indications and formulations of donepezil hydrochloride (Aricept®). With these agreements, 吃瓜大赛黑料头条 will aim to provide a new formulation option and continue to make further contributions to addressing the diversified needs of the people living with Alzheimer’s disease, and to improving their benefits.